Can IVIG help premature Babies' lungs? new trial investigates

NCT ID NCT07561125

Recruiting now Disease control Sponsor: International Peace Maternity and Child Health Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether intravenous immunoglobulin (IVIG) can help treat bronchopulmonary dysplasia (BPD), a serious lung condition, in premature infants born at 28 weeks or earlier. The study will give IVIG to 29 babies and track their breathing support needs and lung health over time. The goal is to see if IVIG reduces the severity of BPD and improves long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intravenous immunoglobulin (IVIG)
What this could lead to: If it works, this could point toward a treatment to reduce lung damage and improve breathing in very premature infants.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply broadly. IVIG can cause side effects like allergic reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHOPULMONARY DYSPLASIA

Contacts and locations

Locations

International Peace Maternity and Child Health Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.